IDYA: Pivotal PFS data for Darovasertib and strong pipeline progress set the stage for major milestones

Key clinical milestones are approaching for Darovasertib in uveal melanoma, with pivotal PFS data expected soon and multiple registrational trials underway. Promising results in DLL3 ADC and MTAP pathway programs highlight a robust pipeline, with several data updates and new combination strategies planned for next year.

Based on IDEAYA Biosciences, Inc. [IDYA] Evercore ISI 8th Annual HealthCONx Conference Audio Transcript — Dec. 3 2025